Regenovo Biotechnology Co., Ltd. provides integrated solutions in 3D printing technology for biomedical applications in China and internationally. The company focuses on developing biomedical 3D printer equipment, materials, and software for regenerative medicine, tissue engineering, drug discovery, and personalized medical applications. It offers research tools for life science and materials science investigators; technology of artificial organs or tissue repair scaffolds for patients with organ defects; print drug screening models and controlled release drug stents for pharmaceutical companies; and print personalized medical devices. The company also provides 3D bioprinters for scientific research; products for drug discovery, personalized medicine, and tissue engineering; biomaterials and scaffold products, 3D printing tissue products, and 3D printing organ models; and professional equipment and technical services for universities, scientific and research institutions, and medical institutions. In addition, it offers drug discovery services, such as liver, tumor, and metabolic syndrome models; and tissue engineering, which include liver tissue, bone tissue, and blood vessel tissue engineering services. The company was founded in 2013 and is headquartered in Hangzhou, China. Regenovo Biotechnology Co., Ltd. operates as a subsidiary of Hangzhou Shining 3D Technology Co., Ltd.